ClinicalTrials.gg
Not yet recruitingNCT06171048Updated Dec 14, 2023

Study Evaluating the Pharmacokinetics of CM310 in Healthy Subjects

A Phase 1 interventional study of CM310 in Healthy, sponsored by Keymed Biosciences Co.Ltd. Not yet recruiting at 1 site in China. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-14.

Sponsored by Keymed Biosciences Co.Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
236
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Male
01

Study summary

This is a single-center, randomized, open-label study to evaluate the pharmacokinetics of CM310 in healthy subjects.

Read the detailed description

This study includes screening and treatment and follow-up periods.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Keymed Biosciences Co.Ltd is the lead sponsor of 68 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 20 years ≤ age ≤ 45 years.
  • Voluntarily participate in the study and sign the ICF.
  • Have the ability to understand the study.

Exclusion criteria

Exclusion Criteria:

  • With history of chronic or serious illness.
  • With any medication within 28 days prior to administration;
  • Plan to undergo surgery during the research period;
  • With any situations unsuitable to participate in this study.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
236 participants (estimated)

Study arms

  • Experimental
    Group A

    CM310 injection, Subcutaneous

    Biological: CM310

  • Experimental
    Group B

    CM310 injection, Subcutaneous

    Biological: CM310

Interventions

  • BiologicalCM310

    CM310 injection

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic: the maximum concentration (Cmax)

    Concentration and exposure

    Time frame: up to week 6

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2024; primary completion for Apr 2025, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2023
First posted
Dec 14, 2023
StartEst.
Apr 30, 2024
Primary completionEst.
Apr 30, 2025
CompletionEst.
Apr 30, 2025
Last update
Dec 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06171048
Responsible party
Sponsor
First posted
Dec 14, 2023
Start date
Apr 30, 2024 (estimated)
Primary completion
Apr 30, 2025 (estimated)
Completion
Apr 30, 2025 (estimated)
Last update
Dec 14, 2023

Study contacts

Qian Jia
Contact
qianjia@keymedbio.com
028-88610620
Wei Hu
principal investigator · The Second Hospital of Anhui Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stapokibart

Start the discussion